UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

> Date of report: July 25, 2019 (Date of earliest event reported)

IDEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 1-10235 (Commission File Number) 36-3555336 (IRS Employer Identification No.)

1925 W. Field Court, Suite 200 Lake Forest, Illinois 60045 (Address of principal executive offices, including zip code)

(847) 498-7070 (Registrant's telephone number, including area code)

Check th	ne appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 - Results of Operations and Financial Condition.

On July 25, 2019, IDEX Corporation (the "Company") issued a press release announcing financial results for the period ended June 30, 2019.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report furnished pursuant to Item 2.02 shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.

Item 7.01 - Regulation FD Disclosure.

O2 2019 Presentation Slides

Presentation slides discussing IDEX Corporation's quarterly operating results are attached to this Current Report on Form 8-K as Exhibit 99.2 and are incorporated herein by reference.

The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand the future prospects of a company and make informed investment decisions. This Current Report and the Exhibits hereto may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as "anticipates," "estimates," "glans," "expects," "forecasts," "should," "could," "will," "management believes," "the company believes," "the company intends," and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors, and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company's results, particularly in light of the low levels of order backlogs it typically maintains; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to

The information in this Current Report furnished pursuant to Items 7.01 and 9.01 shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 9.01 – Financial Statements and Exhibits.

- (a) Exhibits
 - $99.1 \qquad \hbox{Press release dated July 25, 2019 announcing IDEX Corporation's quarterly operating results}$
 - 99.2 Presentation slides of IDEX Corporation's quarterly operating results

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDEX CORPORATION

By: /s/ WILLIAM K. GROGAN

William K. Grogan

Senior Vice President and Chief Financial Officer

July 26, 2019

EXHBIT INDEX

 Exhibit Number
 Description

 99.1
 Press release dated July 25, 2019

 99.2
 Presentation slides of IDEX Corporation's quarterly operating results



For further information: TRADED: NYSE (IEX) EX-99.1

Investor Contact: William K. Grogan Senior Vice President and Chief Financial Officer (847) 498-7070

THURSDAY, JULY 25, 2019

IDEX REPORTS SECOND QUARTER RESULTS; DELIVERS RECORD OPERATING MARGIN AND EPS; RAISES LOW END OF FULL YEAR EPS GUIDANCE

LAKE FOREST, IL, JULY 25 - IDEX Corporation (NYSE: IEX) today announced its financial results for the three month period ended June 30, 2019.

Second Ouarter 2019 Highlights

- · Sales were up 1 percent overall and 3 percent organically
- Reported operating margin was 24.2 percent with adjusted operating margin of 24.5 percent, up 90 bps
- Reported EPS was \$1.48 with adjusted EPS of \$1.50, up 7 percent
- · Acquired Velcora Holding AB in July

Second Quarter 2019

Orders of \$628.1 million were down 2 percent compared with the prior year period (flat organic and -2 percent foreign currency translation).

Sales of \$642.1 million were up 1 percent compared with the prior year period (+3 percent organic and -2 percent foreign currency translation).

Gross margin of 45.5 percent was up 20 basis points compared with the prior year period primarily due to price, volume leverage and productivity initiatives, partially offset by higher engineering investments across all three segments.

Operating income of \$155.3 million resulted in an operating margin of 24.2 percent. Excluding \$2.1 million of restructuring expenses, adjusted operating income was \$157.4 million with an adjusted operating margin of 24.5 percent, up 90 basis points compared with the adjusted prior year period primarily due to gross margin expansion, lower 2019 amortization and variable compensation costs and the stamp duty charge included in the prior year. Adjusted operating income drove adjusted EBITDA of \$177.0 million which was 28 percent of sales and covered interest expense by 16 times.

Provision for income taxes of \$31.4 million in the second quarter of 2019 resulted in an effective tax rate (ETR) of 21.7 percent, which was flat compared with the prior year ETR. The 21.7 percent second quarter ETR was 80 basis points lower than our previously guided rate mainly due to a higher excess tax benefit from stock option exercises.

Net income was \$113.2 million which resulted in EPS of \$1.48. Excluding restructuring expenses, adjusted EPS was \$1.50, an increase of 10 cents, or 7 percent, from the adjusted prior year period EPS

Cash from operations of \$131.2 million led to free cash flow of \$118.3 million, which was up 8 percent from the prior year period and 103 percent of adjusted net income. The increase in free cash flow was primarily due to increased earnings and favorable operating working capital, partially offset by higher capital expenditures in the second guarter of 2019.

The Company repurchased 19 thousand shares of common stock for \$3.0 million in the second quarter of 2019, at an average price of \$154.73.

"Our performance in the second quarter was a great example of how our teams can execute in a volatile environment. Lingering trade tensions during the second quarter caused growth to decelerate across the global economy as companies are employing a wait and see approach in the near term. We also continue to see specific market pressure within our agriculture, semiconductor and auto end markets. In spite of this pressure, we grew organic sales by 3 percent across all three segments. Adjusted operating margin remains a great story, increasing 90 basis points and reaching an all-time quarterly high. Adjusted EPS grew 7 percent and reached a record high of \$1.50. Overall, I am pleased with our second quarter operating results in this choppy environment

Our commitment to invest in the best organic growth opportunities continues to be paramount as the second quarter was our tenth consecutive quarter of organic sales growth. M&A remains a top priority for the Company as well, and last week we announced the acquisition of Velcora Holding, a great addition to our Sealing Solutions platform within our Health & Science segment. The M&A funnel is strong, and our balance sheet has significant capacity to support additional opportunities.

Despite the flat order growth in the second quarter and an uncertain macro environment, we expect to continue our streak of quarterly organic sales growth and margin expansion for the balance of the year. As a result, we are raising the low end of our full year earnings guidance by 8 cents. Full year 2019 adjusted EPS is now projected to be \$5.78 to \$5.85, with full year organic revenue growth expectations of 3 to 4 percent. Third quarter EPS is projected to be \$1.45 to \$1.47, with organic revenue growth of approximately 3 percent."

Andrew K. Silvernail
Chairman and Chief Executive Officer

Second Quarter 2019 Segment Highlights

Fluid & Metering Technologies

- Sales of \$246.2 million reflected a 1 percent increase compared to the second quarter of 2018 (+3 percent organic and -2 percent foreign currency translation).
- Operating income of \$74.1 million resulted in an operating margin of 30.1 percent. Excluding \$0.9 million of restructuring expenses, adjusted operating income was \$75.0 million with an adjusted operating margin of 30.5 percent, a 100 basis point increase compared to the adjusted prior year period primarily due to higher volume, price and productivity initiatives, partially offset by higher engineering investments.
- EBITDA of \$79.5 million resulted in an EBITDA margin of 32.3 percent. Excluding \$0.9 million of restructuring expenses, adjusted EBITDA of \$80.4 million resulted in an adjusted EBITDA margin of 32.7 percent, a 110 basis point increase compared to the adjusted prior year period primarily due to increased operating income.

Health & Science Technologies

- Sales of \$232.3 million reflected a 2 percent increase compared to the second quarter of 2018 (+3 percent organic, +1 percent acquisition and -2 percent foreign currency translation).
- Operating income of \$56.8 million resulted in an operating margin of 24.4 percent. Excluding \$0.3 million of restructuring expenses, adjusted operating income was \$57.1 million with an adjusted operating margin of 24.6 percent, a 100 basis point increase compared to the adjusted prior year period primarily due to higher volume and lower amortization, partially offset by higher engineering investments.
- EBITDA of \$66.3 million resulted in an EBITDA margin of 28.6 percent. Excluding \$0.3 million of restructuring expenses, adjusted EBITDA of \$66.6 million resulted in an adjusted EBITDA margin of 28.7 percent, a 40 basis point increase compared to the adjusted prior year period primarily due to increased operating income.

Fire & Safety/Diversified Products

- Sales of \$164.0 million were flat compared to the second quarter of 2018 (+3 percent organic and -3 percent foreign currency translation).
- Operating income of \$43.6 million resulted in an operating margin of 26.6 percent. Excluding \$0.8 million of restructuring expenses, adjusted operating income was \$44.4 million with an adjusted operating margin of 27.1 percent, a 100 basis point decrease compared to the adjusted prior year period primarily due to product mix and higher engineering investments.
- EBITDA of \$47.5 million resulted in an EBITDA margin of 28.9 percent. Excluding \$0.8 million of restructuring expenses, adjusted EBITDA of \$48.3 million resulted in an adjusted EBITDA margin of 29.4 percent, a 90 basis point decrease compared to the adjusted prior year period primarily due to a decrease in operating income.

For the second quarter of 2019, Fluid & Metering Technologies contributed 38 percent of sales, 42 percent of operating income and 41 percent of EBITDA; Health & Science Technologies accounted for 36 percent of sales, 33 percent of operating income and 34 percent of EBITDA; and Fire & Safety/Diversified Products represented 26 percent of sales, 25 percent of operating income and 25 percent of EBITDA.

Corporate costs decreased to \$19.2 million in the second quarter of 2019 compared to \$21.6 million in the second quarter of 2018, primarily due to the prior year period including a \$2.2 million stamp duty in Switzerland associated with the restructuring of intercompany loans.

In July 2019, the Company acquired Velcora Holding AB and its Roplan and Steridose businesses. Roplan is a global manufacturer of custom mechanical and shaft seals for a variety of end markets including food & beverage, marine, chemical, wastewater and water treatment. Steridose develops engineered hygienic mixers and valves for the global biopharmaceutical industry. Roplan and Steridose, with annual revenue of approximately \$40 million, will operate within the Health & Science Technologies segment.

Non-U.S. GAAP Measures of Financial Performance

The Company supplements certain U.S. GAAP financial performance metrics with non-U.S. GAAP financial performance metrics in order to provide investors with better insight and increased transparency while also allowing for a more comprehensive understanding of the financial information used by management in its decision making. Reconciliations of non-U.S. GAAP financial performance metrics to their most comparable U.S. GAAP financial performance metrics are defined and presented below and should not be considered a substitute for, nor superior to, the financial data prepared in accordance with U.S. GAAP. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below.

- Organic orders and sales are calculated excluding amounts from acquired or divested businesses during the first twelve months of ownership or divestiture and the impact of foreign currency translation.
- Adjusted operating income is calculated as operating income plus restructuring expenses.
- Adjusted operating margin is calculated as adjusted operating income divided by net sales.
- Adjusted net income is calculated as net income plus restructuring expenses, net of the statutory tax expense or benefit.
- EBITDA is calculated as net income plus interest expense plus provision for income taxes plus depreciation and amortization. We reconciled EBITDA to net income on a consolidated basis as we do not allocate consolidated interest expense or consolidated provision for income taxes to our segments.
- Adjusted EBITDA is calculated as EBITDA plus restructuring expenses
- Free cash flow is calculated as cash flow from operating activities less capital expenditures.

Table 1: Reconciliations of the Change in Net Sales to Organic Net Sales

Change in net sales

Reported operating margin

Adjusted operating margin

Reported net income

Adjusted net income

+ Restructuring expenses

+ Tax impact on restructuring expenses

- Net impact from acquisitions

- Impact from FX						(2)%		(2)%		(3)%		(2)%		(2)%		(2)%		(3)%		(2)%
Change in organic net sales					_		3 %		3 %		3 %	_	3 %		5 %		3 %	_	2 %	_	3 %
Table 2: Reconciliations of Reported-	to-Adj	usted Ope	eratin	g Income a	ınd Ma	a rgin (dolla	rs in ti	housands)													
	_										Three Month	s Ende	d June 30,								
	_					2019						_					2018				
	_	FMT		HST		FSDP		Corpora	ate	_	IDEX	_	FMT		HST	_	FSDP		Corporate		IDEX
Reported operating income (loss)	s	74,1	46	\$ 56	763	\$ 43	3,614	\$ (1	19,240)	s	155,283	\$	71,228	\$	52,569	s	45,882	\$	(21,848)	\$	147,831
+ Restructuring expenses	_	9	130		330		819		47		2,126		343		1,123		267		255		1,988
Adjusted operating income (loss)	\$	75,0	76	\$ 57	093	\$ 44	4,433	\$ (1	19,193)	s	157,409	\$	71,571	\$	53,692	\$	46,149	\$	(21,593)	\$	149,819
Net sales (eliminations)	s	246,1	189	\$ 232	253	\$ 164	4,043	s	(386)	s	642,099	\$	242,800	\$	227,403	\$	164,300	\$	(143)	\$	634,360
Reported operating margin		3	0.1%		24.4%		26.6%		n/m		24.2%		29.3%		23.1%		27.99	6	n/m		23.3%
Adjusted operating margin		3	0.5%	:	24.6%		27.1%		n/m		24.5%		29.5%		23.6%		28.19	6	n/m		23.6%
											Six Months En		20								
						2019					Six Months En	1ea Jui	ne 30,				2018				
		FMT		HST		FSDP		Corporate			IDEX	_	FMT		HST		FSDP		Corporate		IDEX
Reported operating income (loss)		146,012	s	110,917	5	83,942	- s	(37,806)	s		303,065	s		s		s	85,436	s	(42,691)	\$	284,514
+ Restructuring expenses	3	930	•	330	3	819	3	(37,606)	3		2,126	3	486	3	2,182	3	367	3	(42,691)	3	3,630
Adjusted operating income (loss)	•	146,942	-	111,247	-	84,761		(37,759)			305,191	s		s	106,557		85,803		(42,096)	s	288,144
Adjusted operating income (loss)	3	140,942	3	111,24/	•	84,761		(37,/59)			303,191	3	15/,880)	100,557	Þ	03,803	a a	(42,096)	Þ	208,144
Net sales (eliminations)	\$	488,711	\$	457,543	\$	320,202	\$	(2,126)	\$		1,264,330	\$	475,133	s	448,478	\$	323,473	\$	(400)	\$	1,246,684

HST

1 %

FSDP

24.0%

24.1%

28.9%

29.0%

2019

113,209

2,126

114,775

(560)

IDEX

HST

2 %

1 %

FMT

3 %

23.3%

23.8%

2018

107,126

1,988

108,620

(494)

Three Months Ended June 30, 26.4%

26.5%

FSDP

(1)%

IDEX

1 %

22.8%

23.1%

2018

206,084

3,630 (873) 208,841

Six Months Ended June 30,

2019

223,477

2,126

225,043

(560)

FMT

24.2%

24.3%

26.2%

26.5%

29.9%

30.1%

Table 3: Reconciliations of Reported-to-Adjusted Net Income and EPS (in thousands, except EPS)

1 %

Reported diluted EPS

+ Restructuring expenses

+ Tax impact on restructuring expenses

Adjusted diluted EPS

EBITDA margin

Diluted weighted average shares outstanding

Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 1.38 2.92 2.65 0.03 0.03 0.03 0.05 (0.01) (0.01) (0.01) (0.01) 1.40 1.50 \$ 2.94 \$ 2.69 76,387 77,704 76,334 77,722

29.8%

Table 4: Reconciliations of EBITDA to Net Income (dollars in thousands)

32.1%

28.3%

										Three Months	Ended J	June 30,								
	_					2019										2018				
	_	FMT		HST		FSDP		Corporate		IDEX		FMT		HST		FSDP		Corporate		IDEX
Reported operating income (loss)	s	74,146	s	56,763	s	43,614	\$	(19,240)	s	155,283	\$	71,228	\$	52,569	\$	45,882	s	(21,848)	\$	147,831
- Other (income) expense - net		239		80		(140)		(557)		(378)		511		(463)		(45)		(53)		(50)
+ Depreciation and amortization	_	5,640		9,635		3,717		172		19,164		5,707		10,090		3,597		176		19,570
EBITDA		79,547		66,318		47,471		(18,511)		174,825		76,424		63,122		49,524		(21,619)		167,451
- Interest expense										11,011										11,140
- Provision for income taxes										31,441										29,615
- Depreciation and amortization										19,164										19,570
Reported net income									s	113,209									\$	107,126
Net sales (eliminations)	s	246,189	s	232,253	s	164,043	\$	(386)	s	642,099	\$	242,800	s	227,403	s	164,300	s	(143)	s	634,360
Reported operating margin		30.1%	6	24.4%		26.6%		n/m		24.2%		29.3%		23.1%		27.9%		n/m		23.3%
EBITDA margin		32.3%	6	28.6%		28.9%		n/m		27.2%		31.5%		27.8%		30.1%		n/m		26.4%
										Six Months End	led Jun	ıe 30,								
						2019										2018				
		FMT		HST		FSDP		Corporate		IDEX		FMT		HST		FSDP		Corporate		IDEX
Reported operating income (loss)	\$	146,012	\$	110,917	\$	83,942	\$	(37,806)	\$	303,065	\$	137,394	\$	104,375	\$	85,436	\$	(42,691)	\$	284,514
- Other (income) expense - net		317		364		365		(1,564)		(518)		645		(1,060)		(3,666)		(418)		(4,499)
+ Depreciation and amortization		11,146		19,142		7,179		356		37,823		11,401		21,479		7,371		373		40,624
EBITDA		156,841		129,695		90,756		(35,886)		341,406		148,150		126,914		96,473		(41,900)		329,637
- Interest expense										21,932										22,140
- Provision for income taxes										58,174										60,789
- Depreciation and amortization										37,823										40,624
Reported net income									\$	223,477									\$	206,084
Net sales (eliminations)	\$	488,711	\$	457,543	s	320,202	s	(2,126)	s	1,264,330	\$	475,133	\$	448,478	s	323,473	s	(400)	\$	1,246,684
Reported operating margin		29.9%		24.2%		26.2%		n/m		24.0%		28.9%		23.3%		26.4%		n/m		22.8%

Table 5: Reconciliations of EBITDA to Adjusted EBITDA (dollars in thousands)

		Three Months Ended June 30,										
			2019						2018			
	FMT	HST	FSDP	Corporate	IDEX	FMT	HST		FSDP	Corporate	IDEX	
EBITDA	\$ 79,547	\$ 66,318	\$ 47,471	\$ (18,511	\$ 174,825	\$ 76,4	24 \$ 63	122 \$	49,524	\$ (21,619)	\$ 167,451	
+ Restructuring expenses	930	330	819	47	2,126	3	43 1	123	267	255	1,988	
Adjusted EBITDA	\$ 80,477	\$ 66,648	\$ 48,290	\$ (18,464	\$ 176,951	\$ 76,7	67 \$ 64	245 \$	49,791	\$ (21,364)	\$ 169,439	
Adjusted EBITDA margin	32.7%	28.7%	6 29.4%	ó n/m	27.6%	3	6%	28.3%	30.3%	n/m	26.7%	
					Six Months l	Ended June 30,						
			2019						2018			
	FMT	HST	FSDP	Corporate	IDEX	FMT	HST		FSDP	Corporate	IDEX	
EBITDA	\$ 156,841	\$ 129,695	\$ 90,756	\$ (35,886	\$ 341,406	\$ 148,1	50 \$ 126	914 \$	96,473	\$ (41,900)	\$ 329,637	
+ Restructuring expenses	930	330	819	47	2,126	4	86 2	182	367	595	3,630	
Adjusted EBITDA	\$ 157,771	\$ 130,025	\$ 91,575	\$ (35,839	\$ 343,532	\$ 148,6	36 \$ 129	.096 \$	96,840	\$ (41,305)	\$ 333,267	
Adjusted EBITDA margin	32.3%	28.49	6 28.6%	ń n/m	27.2%	3	3%	28.8%	29.9%	n/m	26.7%	

Table 6: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (in thousands)

	Three Months Ended					Six Months Ended				
	 June 30,			March 31,		June				
	2019		2018		2019		2019		2018	
Cash flows from operating activities	\$ 131,175	\$	120,697	\$	88,663	\$	219,838	\$	192,426	
- Capital expenditures	 12,867		10,959		12,875		25,742		20,968	
Free cash flow	\$ 118,308	\$	109,738	\$	75,788	\$	194,096	\$	171,458	

Conference Call to be Broadcast over the Internet

IDEX will broadcast its second quarter earnings conference call over the Internet on Friday, July 26, 2019 at 9:30 a.m. CT. Chairman and Chief Executive Officer Andy Silvernail and Senior Vice President and Chief Financial Officer William Grogan will discuss the Company's recent financial performance and respond to questions from the financial analyst community. IDEX invites interested investors to listen to the call and view the accompanying slide presentation, which will be carried live on its website at www.idexcorp.com. Those who wish to participate should log on several minutes before the discussion begins. After clicking on the presentation icon, investors should follow the instructions to ensure their systems are set up to hear the event and view the presentation sildes, or download the correct applications at no charge. Investors will also be able to hear a replay of the call by dialing 877.660.6853 (or 201.612.7415 for international participants) trained the ID #13604163. using the ID #13684163.

Forward-Looking Statements

This news release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as "anticipates," "estimates," "plans," "expects," "projects," "forecasts," "should," "could," "will," "management believes," "the Company believes," "the Company intends," and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company's results, particularly in light of the low levels of order backlogs it typically maintains; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements included here are only made as of the date of

About IDEX

IDEX (NYSE: IEX) is a company that has undoubtedly touched your life in some way. In fact, IDEX businesses make thousands of products that are mission-critical components in everyday activities. Chances are the car you're driving has a BAND-IT® clamp holding your side airbag safely in place. If you were ever in a car accident, a Hurst Jaws of Life® rescue tool may have saved your life. If you or a family member is battling cancer, your doctor may have tested your DNA in a quest to find the best targeted medicine for you. It's likely your DNA test was run on equipment that contains components made by our growing IDEX Health & Science team. Founded in 1988 with three small, entrepreneurial manufacturing companies, we're proud to say that we now call 40 diverse businesses around the world part of the IDEX family. With 7,000 employees and manufacturing operations in more than 20 countries, IDEX is a high-performing, global \$2+ billion company committed to making trusted solutions that improve lives. IDEX shares are traded on the New York Stock Exchange under the symbol "IEX".

For further information on IDEX Corporation and its business units, visit the company's website at www.idexcorp.com.

(Financial reports follow)

IDEX CORPORATION

Condensed Consolidated Statements of Operations
(in thousands except per share amounts)
(unaudited)

	Three Months Ended June 30,				nths Ended ine 30,		
		2019		2018	2019		2018
Net sales	\$	642,099	\$	634,360	\$ 1,264,330	\$	1,246,684
Cost of sales		349,762		346,993	688,159		682,665
Gross profit		292,337		287,367	576,171		564,019
Selling, general and administrative expenses		134,928		137,548	270,980		275,875
Restructuring expenses		2,126		1,988	2,126		3,630
Operating income		155,283		147,831	303,065		284,514
Other (income) expense - net		(378)		(50)	(518)		(4,499)
Interest expense		11,011		11,140	21,932		22,140
Income before income taxes		144,650		136,741	281,651		266,873
Provision for income taxes		31,441		29,615	58,174		60,789
Net income	\$	113,209	\$	107,126	\$ 223,477	\$	206,084
Earnings per Common Share:							
Basic earnings per common share	\$	1.50	\$	1.40	\$ 2.96	\$	2.69
Diluted earnings per common share	\$	1.48	\$	1.38	\$ 2.92	\$	2.65
Share Data:							
Basic weighted average common shares outstanding		75,460		76,539	75,450		76,479
Diluted weighted average common shares outstanding		76,387		77,704	76,334		77,722

IDEX CORPORATION
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

	June 30, 2019			
Assets	 			
Current assets				
Cash and cash equivalents	\$ 543,189	\$	466,407	
Receivables - net	326,358		312,192	
Inventories	301,006		279,995	
Other current assets	46,329		33,938	
Total current assets	1,216,882		1,092,532	
Property, plant and equipment - net	275,025		281,220	
Goodwill and intangible assets	2,063,073		2,081,282	
Other noncurrent assets	85,235		18,823	
Total assets	\$ 3,640,215	\$	3,473,857	
Liabilities and shareholders' equity				
Current liabilities				
Trade accounts payable	\$ 160,579	\$	143,196	
Accrued expenses	162,838		187,536	
Short-term borrowings	452		483	
Dividends payable	37,922		33,446	
Total current liabilities	361,791		364,661	
Long-term borrowings	848,555		848,335	
Other noncurrent liabilities	317,828		266,221	
Total liabilities	1,528,174		1,479,217	
Shareholders' equity	2,112,041		1,994,640	
Total liabilities and shareholders' equity	\$ 3,640,215	\$	3,473,857	

IDEX CORPORATION

Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

	Six Mo	nths Ended Ju	Ended June 30,		
	2019		2018		
Cash flows from operating activities					
Net income	\$ 223,47	7 \$	206,084		
Adjustments to reconcile net income to net cash provided by operating activities:					
Depreciation and amortization	19,87	0	19,957		
Amortization of intangible assets	17,95	3	20,667		
Amortization of debt issuance expenses	66	9	664		
Share-based compensation expense	14,41	3	13,252		
Deferred income taxes	10,68	5	(3,021)		
Non-cash interest expense associated with forward starting swaps	3,17	1	3,259		
Changes in (net of the effect from acquisitions):					
Receivables	(14,17	7)	(40,044)		
Inventories	(21,00	7)	(28,011)		
Other current assets	(12,38	2)	17,798		
Trade accounts payable	17,27	6	5,432		
Accrued expenses	(39,60	2)	(21,131)		
Other - net	(50	8)	(2,480)		
Net cash flows provided by operating activities	219,83	8	192,426		
Cash flows from investing activities					
Purchases of property, plant and equipment	(25,74	2)	(20,968)		
Purchase of intellectual property	-	_	(4,000)		
Proceeds from disposal of fixed assets	78	0	_		
Other - net	50	1	(861)		
Net cash flows used in investing activities	(24,46	1)	(25,829)		
Cash flows from financing activities					
Dividends paid	(71,28	3)	(61,916)		
Proceeds from stock option exercises	20,76		13,616		
Purchases of common stock	(54,66		(19,499)		
Shares surrendered for tax withholding	(11,50		(10,750)		
Settlement of foreign exchange contracts	· · ·		6,593		
Other - net	(1,92	9)	_		
Net cash flows used in financing activities	(118,62	8)	(71,956)		
Effect of exchange rate changes on cash and cash equivalents	3		(11,840)		
Net increase in cash	76,78		82,801		
Cash and cash equivalents at beginning of year	466,40		375,950		
Cash and cash equivalents at end of period	\$ 543.18		458,751		

IDEX CORPORATION

Company and Segment Financial Information - Reported (dollars in thousands)

(unaudited)

(unu	auncu)	Three Months Ended June 30, (a)			Six Months Ended June 30, (a)			
		2019		2018		2019	2019	
Fluid & Metering Technologies		_		_				_
Net sales	\$	246,189	\$	242,800	\$	488,711	\$	475,133
Operating income (b)		74,146		71,228		146,012		137,394
Operating margin		30.1%		29.3%		29.9%		28.9%
EBITDA	s	79,547	\$	76,424	\$	156,841	\$	148,150
EBITDA margin		32.3%		31.5%		32.1%		31.2%
Depreciation and amortization	s	5,640	\$	5,707	\$	11,146	\$	11,401
Capital expenditures		3,350		3,981		6,580		8,655
Health & Science Technologies								
Net sales	\$	232,253	\$	227,403	\$	457,543	\$	448,478
Operating income (b)		56,763		52,569		110,917		104,375
Operating margin		24.4%		23.1%		24.2%		23.3%
EBITDA	s	66,318	\$	63,122	\$	129,695	\$	126,914
EBITDA margin		28.6%		27.8%		28.3%		28.3%
Depreciation and amortization	s	9,635	\$	10,090	\$	19,142	\$	21,479
Capital expenditures		5,913		5,351		11,217		8,682
Fire & Safety/Diversified Products								
Net sales	s	164,043	\$	164,300	\$	320,202	\$	323,473
Operating income (b)		43,614		45,882		83,942		85,436
Operating margin		26.6%		27.9%		26.2%		26.4%
EBITDA	s	47,471	\$	49,524	\$	90,756	\$	96,473
EBITDA margin		28.9%		30.1%		28.3%		29.8%
Depreciation and amortization	\$	3,717	\$	3,597	\$	7,179	\$	7,371
Capital expenditures		3,534		1,627		6,487		3,445
Corporate Office and Eliminations								
Intersegment sales eliminations	\$	(386)	\$	(143)	\$	(2,126)	\$	(400)
Operating income (b)		(19,240)		(21,848)		(37,806)		(42,691)
EBITDA		(18,511)		(21,619)		(35,886)		(41,900)
Depreciation and amortization		172		176		356		373
Capital expenditures		70		_		1,458		186
Company								
Net sales	\$	642,099	\$	634,360	\$	1,264,330	\$	1,246,684
Operating income		155,283		147,831		303,065		284,514
Operating margin		24.2%		23.3%		24.0%		22.8%
EBITDA	s	174,825	\$	167,451	\$	341,406	\$	329,637
EBITDA margin		27.2%		26.4%		27.0%		26.4%
Depreciation and amortization (c)	s	19,164	\$	19,570	\$	37,823	\$	40,624
Capital expenditures		12,867		10,959		25,742		20,968

IDEX CORPORATION

Company and Segment Financial Information - Adjusted (dollars in thousands)

(unaudited)

		Three Months Ended June 30, (a)			Six Months Ended June 30, (a)			
		2019	2018		2019		2018	
Fluid & Metering Technologies								
Net sales	\$	246,189	\$ 242,800	\$	488,711	\$	475,133	
Adjusted operating income (b)		75,076	71,571		146,942		137,880	
Adjusted operating margin		30.5%	29.5%		30.1%		29.0%	
Adjusted EBITDA	\$	80,477	\$ 76,767	\$	157,771	\$	148,636	
Adjusted EBITDA margin		32.7%	31.6%		32.3%		31.3%	
Depreciation and amortization	\$	5,640	\$ 5,707	\$	11,146	\$	11,401	
Capital expenditures		3,350	3,981		6,580		8,655	
Health & Science Technologies								
Net sales	s	232,253	\$ 227,403	\$	457,543	\$	448,478	
Adjusted operating income (b)		57,093	53,692		111,247		106,557	
Adjusted operating margin		24.6%	23.6%		24.3%		23.8%	
Adjusted EBITDA	\$	66,648	\$ 64,245	\$	130,025	\$	129,096	
Adjusted EBITDA margin		28.7%	28.3%		28.4%		28.8%	
Depreciation and amortization	s	9,635	\$ 10,090	\$	19,142	\$	21,479	
Capital expenditures		5,913	5,351		11,217		8,682	
Fire & Safety/Diversified Products								
Net sales	\$	164,043	\$ 164,300	\$	320,202	\$	323,473	
Adjusted operating income (b)		44,433	46,149		84,761		85,803	
Adjusted operating margin		27.1%	28.1%		26.5%		26.5%	
Adjusted EBITDA	s	48,290	\$ 49,791	\$	91,575	\$	96,840	
Adjusted EBITDA margin		29.4%	30.3%		28.6%		29.9%	
Depreciation and amortization	\$	3,717	\$ 3,597	\$	7,179	\$	7,371	
Capital expenditures		3,534	1,627		6,487		3,445	
Corporate Office and Eliminations								
Intersegment sales eliminations	s	(386)	\$ (143)	\$	(2,126)	\$	(400)	
Adjusted operating income (b)		(19,193)	(21,593)		(37,759)		(42,096)	
Adjusted EBITDA		(18,464)	(21,364)		(35,839)		(41,305)	
Depreciation and amortization		172	176		356		373	
Capital expenditures		70	_		1,458		186	
Company								
Net sales	s	642,099	\$ 634,360	\$	1,264,330	\$	1,246,684	
Adjusted operating income		157,409	149,819		305,191		288,144	
Adjusted operating margin		24.5%	23.6%		24.1%		23.1%	
Adjusted EBITDA	\$	176,951	\$ 169,439	\$	343,532	\$	333,267	
Adjusted EBITDA margin		27.6%	26.7%		27.2%		26.7%	
Depreciation and amortization (c)	\$	19,164	\$ 19,570	\$	37,823	\$	40,624	
Capital expenditures		12,867	10,959		25,742		20,968	

⁽a) Three and six month data includes the results of Finger Lakes Instrumentation (tuly 2018) in the Health & Science Technologies segment from the date of acquisition.
(b) Segment operating income excludes unallocated corporate operating expenses which are included in Corporate Office and Eliminations.
(c) Depreciation and amortization excludes amortization of debt issuance costs.





Second Quarter 2019 Earnings

July 26, 2019

AGENDA

- IDEX's Overview and Outlook
- Q2 Financial Performance
- Segment Performance
 - Fluid & Metering Technologies
 - · Health & Science Technologies
 - Fire & Safety / Diversified Products
- 2019 Guidance Summary
- Q&A



Replay Information

Dial toll–free: 877.660.6853

International: 201.612.7415

Conference ID: #13684163

Log on to: www.idexcorp.com




Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures


This presentation and discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as "anticipates," "estimates," "plans," "expects," "projects," "forecasts," "should," "could," "will," "management believes," "the company believes," "the company intends," and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the following: economic and political consequences resulting from terroris attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world pricing pressures and other competitive factors, and levels of capital spending in certain industries – all of which coulc have a material impact on order rates and IDEX's results, particularly in light of the low levels of order backlogs it typically maintains; its ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the company operates; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the other risks discussed in the company's m


This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included eithe in this presentation or our earnings release for the three-month period ending June 30, 2019, which is available on our website.

















* Operating margin and EPS data adjusted for restructuring expenses (\$2.1M in Q2 2019 and \$2.0M in Q2 2018).

Organic sales growth of 3 percent drove a 90 bps increase in operating margin









Q2 Sales Mix:	Organic	3%
	FX	<u>-2%</u>
	Reported Sales	1%


Q2 Highlights:

- Segment continued to expand through targeted growth initiatives despired choppiness in day rate business
- □ Favorable OEM and project wins drove record sales in our Viking and Ric businesses
- ☐ Municipal water remained steady and Oil & Gas market conditions stabi
- ☐ Banjo contracted due to overall worsening agriculture industry dynamic

Organic sales growth of 3 percent drove a 100 bps increase in operating margi



^{*} Operating margin data adjusted for restructuring expenses (\$0.9M in Q2 2019 and \$0.3M in Q2 2018).



Operating margin data adjusted for restructuring expenses (\$0.3M in Q2 2019 and \$1.1M in Q2 2018).

Organic sales growth of 3 percent drove a 100 bps increase in operating marg



Fire & Safety / Diversified Products

(Dollars in m



Operating margin data adjusted for restructuring expenses (\$0.8M in Q2 2019 and \$0.3M in Q2 2018).

Organic sales growth of 3 percent



2019 Guidance Summary

Q3 2019

- EPS estimate range: \$1.45 - \$1.47

- Organic revenue growth: ~3%

- Operating margin: ~24.0%

- Tax rate: ~22.5%

- FX impact: ~1.0% topline headwind based on June 30, 2019 FX rates

- Corporate costs: ~\$20 million

FY 2019

- EPS estimate range: \$5.78 - \$5.85

- Organic revenue growth: 3 - 4%

- Operating margin: ~24.0%

- FX impact: ~1.0% topline headwind based on June 30, 2019 FX rates

- Other modeling items:

Tax rate: ~21.5%Cap Ex: > \$60M

- Free cash flow will be approximately 105% of net income
- Corporate costs: \$78 \$80 million
- · EPS estimate excludes all future acquisitions and associated costs and any future restructuring expenses

